An observational study in Atrial Fibrillation, Inflammation and Genetic Predisposition to Disease, sponsored by Vrinnevi Hospital. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Vrinnevi Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.
Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 30th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2023, is one of 40 observational ones, reaches primary completion later than 6 of the 35 other live ones, and was the 123rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska University Hospital · Sites in Sweden
Ages 78+
Emma Svennberg · Sites in Sweden
Ages 18+
Rahul Raj · Sites in Sweden, Finland
Ages 18+
Region Stockholm · Sites in Sweden
Ages 55+
Johan Sundström · Sites in Sweden
Ages 50–75 · Healthy volunteers
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 30 · Phase 4 6
First in 1993; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 182 is below the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 361 across the 95 interventional studies, 480 across the 39 observational. Of the 85 that completed or were terminated, 34 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 135 have an industry lead sponsor. The 10 most frequent:
Vrinnevi Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Vrinnevi Hospital has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
5 of the studies in Atrial Fibrillation with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696079Rahul RajRestarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation | 2026-12 |
| NCT04593498Karolinska InstitutetExcessive Supraventricular Activity and Atrial Fibrillation | 2026-12-31 |
| NCT06656884Boston Scientific CorporationFARAPULSE Workflow Assessment Registry | 2027-02-15 |
| NCT07181590Abbott Medical DevicesBaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF | 2027-09 |
| NCT06315192Region SkaneStroke Alarm Efficacy Trial | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 135 studies in Atrial Fibrillation with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value.
This prospective cohort study is planning to include 182 patients with persistent atrial fibrillation, planned for electrical cardioversion, and \>18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG.
An interim analysis will be conducted after more than 80 patients have been included. If the results from univariate and/or multivariable logistic regression on inflammatory markers and genetic expression regarding atrial fibrillation recurrence are significant, the study will be concluded.
The study included patients aged 18 or older diagnosed with persistent atrial fibrillation (ICD-10 I48.1) scheduled for ECV. Inclusion took place from 2023-10-18 to 2025-06-01.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospective cohort measuring the previously described biomarkers.
Other: Blood sampling
Blood sampling
Recurrence of AF
Recurrence of atrial fibrillation or atrial flutter recorded on 12-lead ECG or through pacemaker interpretation
Time frame: During follow-up (post ECV, day 7, 30, 90, and 180)
Fluctuations of biomarkers and gene expression during follow-up
Change in biomarker level or expression of gene expressions during follow-up.
Time frame: During follow-up (post ECV, day 7, 30, 90, and 180)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Jun 2025, 19 months after the start.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 19 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vrinnevi Hospital